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EDITORIAL 
Distinguishing Cancer and N oncancer 
The article "Monoclonal antibodies selected to discriminate 
between malignant melanomas and nevocellular nevi" by 
Ruiter eta! pub lished in this issue [1) raises impot tant ques-
tions about the diagnosis of melanoma in particular and of 
primary cancer in general. An antibody or any other modality 
that reliably served to discriminate between a benign condition 
like a nevus and a malignancy like a melanoma would obviously 
be valuable in clinical practice. f'urther, such a modality (or 
"test" for cancer) could lead to potentially even greater benefits 
in elucidating t he fundamental question of why some tumors 
or tumor- like lesions, such as nevi, are benign, while others 
metastasize and kill patients. Unfortunately, no s uch absolutely 
specific test for cancer has been discovered to date. Indeed, the 
lack of such a test can be viewed as a rather fundamental 
problem of tumor biology, and as an important reason for our 
current lack of consistent success not only in diagnosis but also 
in treatment of cancer, for one cannot fu lly understand and 
treat what one cannot reliably recognize. 
The difficulties inherent in caocer diagnosis and treatment 
are both fundamenta l and practical. The fundarnenta l difficul-
t ies begin with the definition of the disease. What, indeed, is 
cancer? The answer is not immediately obvious. To paraphrase 
the late Leslie Foulds, "cancer" is primarily a clinical term, and 
histologic diagnosis is merely in ferential [2]. The clinical term 
"cancer" is commonly taken to indicate a neoplastic process 
that has a meaningful chance of killing a patient. Since very 
few patients are killed by locali zed primary tumors, a require-
ment for the diagnosis of cancer is that the lesion be capable 
of ("competent for") metastasis. Thus, the problem becomes 
that of the recognition of those tumors that have acquired 
"competence for metastasis." There are, in the present state of 
our knowledge, no tests perfectly predictive of competence for 
metastasis of a primary tumor in stage I, and thus there are no 
thoroughly reliab le tests for "cancer." 
The present method of diagnosis of cancer is one of pattern 
recognition and hypothesis testing. To take !Gelanoma diag-
nosis as an example, the process begins with the recognition 
that one lesion out of a large universe of pigmented cutaneous 
lesions is somehow different. The patient may perceive a chancre 
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m this lesion, and the clinician may recogmze a well -described 
and codified pattern, such as a broad asymmetric plaque with 
irregular borders and heterogeoeous colors including blue-
black. Such circumstances gener::~te an hypothesis in the mind 
of the clinician- that the les ion may be a melanoma- and th is 
hypothesis is tested by submitting the lesion for histologic 
study. Grossly and at scanning microscopic magnification, the 
pathologist in turn may recognize a familiar pattern and form 
the hypothesis that the lesion 'is a melanoma. He then, at 
higher magnification, tests this hypothesis by seeking certain 
features- mitotic figures, invasion, lymphocytes, and so on-
that are more or less reliably associated with a diagnosis of 
melanoma as we currently recog1lize it (3). 
In clinical parlance, the set of hypotheses generated by 
pattern recognition is generally termed a "differential diagno-
sis," and the tests of that hypothesis are termed "criteria for 
diagnosis." If all of t he criteria are satisfied, a diagnosis is 
made, and the physicians are satisfied that their diagnostic 
task has been accomplished. The patient indubitably has "ma-
lignant melanoma," but does not necessar ily have "cancer," if 
the definition of "cancer" as a les ion with competence for 
metastasis is followed . Even with present means one can iden-
tify subsets of patients with malignant melanoma whose risk 
of metastasis is indistinguishable from zero [ 4), and even in the 
highest apparent risk categories there are long-term disease-
free survivors. These may be individuals whose host status is 
not "accepting" of metastasis, so that "competence for metas-
tasis" is a property not only of tumors, but also of their hosts. 
If we could identify patients whose tumors lack competence 
for metastasis, we might well conclude that they do not have 
cancer at all, but rather a benign simulant. Some such lesions 
might be truly benign lesions, such as Spitz nevi. Others might 
indeed possess all of the properties associated with competence 
for metastasis in most hosts, yet these properties may be 
insufficient to overcome defense mechanisms in a particular 
host. Yet others might have had a greater or lesser risk of 
developing competence for metastasis if they had been left in 
place, such as in situ melanomas, which as far as we know are 
quite likely to progress to invasive and then high-risk melano-
mas if not excised, or like dysplastic nevi, which progress ~o 
melanoma in only a small proportion of cases [5]. Dysplastic 
nevi, which may be present in 5% of "normal" populations 
[6), clearly are not "cancers." Further, the term "in situ malig-
nant melanoma" appears inappropriate for a lesion that never 
metastasizes, though simple therapy of an in situ melanoma is 
clearly indicated because of its potential for future progression 
to a frank ly malignant tumor. 
The nature of competence for metastasis is only now in the 
process of becoming understood at the phenomenologic and 
biochemical levels. A tumor or tumor ce ll, to metastasize, must 
be endowed with formidable properties that are not found in 
normal cells [7] . Further, it is likely that "cancer" also requires 
host part icipation, possibly even an active acquiescence. Mel-
anoma cell(s) in the epidermis, for example, must be capable 
(1) of "invasion" into the dermis, and (2) of survival there, 
perhaps in the face of (or alternatively [8), with the assistance 
of) an immunologic response. The tumor must be capable of 
(3) physically migrating ("infiltrating") into the regi~n of a 
blood vessel and then of (4) penetrating its wall. Then, It must 
(5) break off and circulate for a time, evading any tumoricidal 
host responses, then (6) reverse the angioinvasive process at a 
distant site, establish itself in a remote organ (7) and t hen (8) 
proliferate there to form the clinical mass lesion tht we term a 
"metastasis" (there is no evidence that patients are harmed by 
"micrometastases" that do not proliferate at the remote site). 
To successfully metastasize, a tumor must exhibit each and 
every one of these properties, like a golfer who has not com-
pleted his round until he has played every hole. No matter how 
well a tumor "scores" at the first "hole" (invasion of the dermis), 
it will not metastasize unless it can also survive in the circula-
tion and so on. 
It is a virtual axiom of modern biology that function, or 
phenomenology, follows and is dependent on events at the 
cellular and biochemical levels. Further, the "central dogma" 
of molecular biology states that molecular events in cells are 
determined by the genome. Thus, the processes associated with 
"competence for metastasis" should, in theory, be subject to 
biochemical evaluation. Monoclonal antibodies are tools that 
are well suited to evaluate gene products, while other tools such 
as DNA probes are now widely available for the study of the 
genome itself. As such modalities are applied to tumors, we 
may confidently expect an ever increasing understanding of the 
enigmatic "cancer cell." At the same time, we may hope to 
discover tests for cancer in addition to the traditional ones 
discussed above. The likelihood that any one, or any very small 
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number, of such tests will be absolutely predictive of compe-
tence for metastasis, however, is remote, because of the complex 
nature of the metastatic phenomenon. Thus, in the simple 
examples of properties associated with metastatic competence 
cited above, and presuming that each separate property is 
associated with qualitative or quantitative changes in only one 
molecule (a tenuous assumption at best), at least eight separate 
monoclonal antibodies or gene probes would be required to 
make a specific diagnosis of cancer. In fact, of course, it is quite 
likely that each of the broad properties mentioned above could 
be separated into dozens of specific cellular events, each asso-
ciated with its own set of biochemical alterations. 
These considerations do not imply that biochemical data as 
revealed by monoclonal antibodies or other means cannot be 
of use in diagnosis of cancer, but that their role at least in the 
near future will be a limited one. Immunopathologic studies at 
present are of greatest use in assessing the differentiation of 
tumors, a feature that correlates only very loosely with "malig-
nancy." In the future, one can expect antibody panels of the 
sort described by Ruiter et al [1] to take their place in the 
pathologist's armamentarium as one of many tools that aid in 
the diagnostic hypothesis-testing role. Just as "invasion" is 
commonly, but not necessarily, correlated with competence for 
metastasis, so it may be that a given antigen (or gene) may 
independently identify tumors that are at risk of metastasis. 
As the number of available tests of the diagnostic hypothesis 
increases, we may expect a useful increase in our diagnostic 
precision, provided that important practical questions relating 
to the reproducibility, sensitivity, specificity, and predictive 
value [9] of these tests, taken singly and in combination, are 
properly addressed. 
For these practical reasons, it is premature to recommend 
the routine use of currently available tumor-associated antigens 
for diagnosis of malignant tumors in clinical practice (other 
than for the assessment of differentiation antigens like thyro-
globulin in a suspected thyroid carcinoma, where the diagnosis 
of malignancy has already been made). The umbra of scientific 
validity cast by a sophisticated test like a monoclonal antibody 
stain should not obscure the responsibility of pathologists to 
carefully assess its predictive value in making the important 
choice between such alternatives as "cancer" and "noncancer." 
This is particularly true when a new method of hypothesis-
testing (like monoclonal antibodies) becomes available as a 
possible complement or alternative to those traditional modal-
ities that have survived the more informal evaluation of a 
century or more of time and experience. 
The first phase of the evaluation of a new test encompasses 
its application to a group of patients (or lesions) that indisput-
ably satisfy the other, traditional, criteria for the disease, for 
example, to a group of lesions of malignant melanoma that 
have been carefully evaluated by a reference panel of patholo-
gists. Since there are some heterogeneities among melanomas, 
the evaluation group of cases should be representative of all 
the major types and tumor progression stages. Then, in the 
second phase of initial evaluation, the test is as a rule applied 
to a group of patients (lesions) that have no evidence of the 
disease. The test should be performed on multiple samples of 
the same lesion to determine its reproducibility, or the proba-
bility that the same result will be obtained when the test is 
repeated. This is particularly important when observer judge-
ment is involved (when, for example, a particular pattern of 
staining, or a defined percentage of reactive cells, is required to 
satisfy the criteria for a "positive" test). The lesions evaluated 
should include those that are relevant and also some that are 
irrelevant to the circumstances in which the test will be used. 
For example, if it is envisaged that a monoclonal antibody 
might be run by a computerized analyzer on all the specimens 
that enter a surgical pathology laboratory to "rule out mela-
noma," then a representative sample of all such lesions must 
be evaluated. On the other hand, if it is certain that the test 
will never be applied to a sweat gland tumor or a lung tumor, 
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then such lesions may be of lesser relevance in an initictl 
evaluation. In practice, however, some information about seem-
ingly irrelevant specificities will be required to assess the reli-
ability of the test in situations for which it was not designed, 
or to accurately define the circumstances in which it is appro-
priate to use the test. 
The data from the first phase of evaluation (reactivity with 
defined lesions of melanoma) provide important baseline infor-
mation not only about the reproducibility of the test, but also 
about its sensitivity, or its ability to give a positive result when 
the lesion truly represents the disease (melanoma) under study. 
The second phase (reactivity with benign lesions) gives infor-
mation about the specificity of the test, or its ability to give a 
negative result when the lesion is not melanoma. For exampl~, 
if an antibody correctly identified 99 of 100 "melanomas," as 
judged by a reference panel of pathologists using tradition&! 
means of diagnosis, its sensitivity is 99%. If the same antibody 
stained one of 100 benign nevi, it correctly identified 99 nevi 
as negative for "melanoma," and showed a false-positive result 
in one, for a specificity of 99%. 
More important than these crude sensitivity and specificity 
data in evaluating the clinical utility of a test is an estimate of 
its predictive value. This value cannot be estimated directly 
from data of the sort described above, since they are, of neces-
sity, likely to be based on selected cases. The positive predictive 
value of a test is the likelihood that a lesion yielding a positive 
test actually is a melanoma, and the negative predictive value 
is the likelihood that a lesion yielding a negative test actually 
is not a melanoma. The predictive value of a test depends on 
the prevalence of the disease in the population. Further, i.t 
depends on the disease prevalence in that specific population 
which is subject to evaluation by the application of the test 
and this depends in turn on the use to which the test is put: 
The predictive value of a test is quite different for a sample 
based on a whole population than for a selected subset of that 
population. 
The predictive value of a test to discriminate nevi from 
melanomas depends on the relative frequency of the two lesions 
in the population. For example, there may be over 6000 nevi in 
the population for every melanoma [5] . If a test with the 
specificity and sensitivity described above were applied to every 
one of these 6001 pigmented lesions, 6000 X 99% of the nevi 
or 5940, would be identified correctly as "not melanoma," but 
there would be 6000 X 1% or 60 false positives for each "true" 
melanoma, which would be recognized correctly by the test in 
99% of cases. The predictive value of a positive test is given by 
the number of "true" melanomas with a positive test (0.99) 
divided by the total number of lesions with a positive test 
(60.99). In the example above, which does not even consid~r 
the difficulties that might be engendered by pigmented sebor-
rheic keratoses and other pigmented lesions with high but 
unknown prevalence in the community, the positive predictive 
value is 0.99/60.99, or only 1.6%. 
The predic~iv~ value of a test :an be enhanced by altering 
the charactenst1cs of the populatiOn to be screened, that is by 
preselection of the group to be tested. In considering whether 
or not to biopsy a lesion and submit it for histologic examina-
tion, a clinician is selecting a special group of lesions. Then, a 
pathologist who predetermined that he would use a monoclonctl 
antibody to evaluate all pigmented lesions that entered hi.s 
laboratory would be evaluating a different population from that 
considered in the above assumptions. If one assumes that a 
pathologist sees, say, 500 benign nevi for every melanoma, then 
the predictive value of the hypothetical antibody test described 
above would be about 20%. Much more likely, however, is th.e 
possibility that the pathologist will choose to apply this expen-
sive and time-consuming test to a group of cases that he himself 
selects from among his own "population" of pigmented lesion ~g. 
These will be "difficult" or "borderline" lesions, many of whicl) 
for example, might be dysplastic nevi . ' 
If one assumes that a pathologist sees only, say, 10 "difficult" 
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dysplastic nevi for every melanoma, then the apparent predic-
tive value of our hypothetical monoclonal antibody would be 
0.99/[(10 X 0.01) + 0.99], or about 90%. However, t his consid-
eration ignores a very important assumption, relating to the 
validity of t he original sensitiv ity and specificity data when 
applied to such a highly se lected group. It is by no means proper 
to assume t hat data derived from a general population of 
common nevi, perhaps including a few histologically character-
istic dysplastic nevi, can be used to generate reliable conclusions 
about a group of dysplastic nevi selected for t heir cliagnostic 
difficulty because of clinical and/or histologic resemblances to 
"true" melanomas. Thus, if an antibody is to be used in this 
manner (as would seem likely to be the case were it introduced 
into general practice), the sensitivity and specificity phase of 
its evaluation must be repeated using a population of lesions 
matched to those to which the antibody will be applied. Then, 
the results of such a test in actual practice must be interpreted 
in the light of the user's estimate of the relative frequencies of 
the lesions in his own population of diagnostically cha llenging 
cases. 
Thus, when monoclonal antibodies or other molecular probes 
that seek to discriminate "cancer" from "noncancer" come into 
use, t he importance of the pattern-recognition step in the 
diagnostic process will be undiminished since it is likely that 
the complex panels of molecular probes will be applicable on ly 
to appropriately selected cases. These panels of diagnostic tests 
(antibodies, gene probes, biochemical analyses, and so on) will 
be used as adjuncts to the hypothesis-testing ("different ial") 
mode of diagnosis of selected cases where the predictive value 
of the test(s) has been shown to be high. If t hose tumors with 
competence for metastasis can be prospectively identified by 
such means, whether or not in combination with traditional 
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clinical and pathologic tools, and particularly if these advances 
in diagnostic ability are concomitant with improved under-
standing of the metastatic process itself, it may be possible to 
develop more effective forms of therapy against this most 
serious expression of the disease we call "cancer." 
David E. Elder, M.B., Ch.B. 
University of Pennsylvania School of Meclicine 
Phi ladelphia, Pennsylvania 
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